Vobarilizumab: Difference between revisions

Vobarilizumab
[[File:\|frameless\|220px\|alt=\|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	1628814-88-9
PubChem
DrugBank
ChemSpider	none
KEGG	D11005

Vobarilizumab (ALX0061) (INN) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.<ref>Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association.</ref><ref>World Health Organization,

 International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114, 
 WHO Drug Information, 
 2015,
 Vol. 29(Issue: 4),
 
 
 
 
 
 Full text,</ref>

This drug was developed by Ablynx NV.

References[edit]

Monoclonal antibodies for the immune system

Immune system

Human	* Immunosuppression: Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	* Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	* Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	* Immunosuppressive: Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	* Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	* Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	* Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	* Lokivetmab

Inflammatory lesions

Mouse

* Besilesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.

Revision as of 03:56, 11 February 2025 edit Prab (talk \| contribs) , Bureaucrats, Interface administrators, Administrators 1,432,208 edits CSV import ← Older edit	Latest revision as of 13:30, 18 March 2025 edit undo Prab (talk \| contribs) , Bureaucrats, Interface administrators, Administrators 1,432,208 edits No edit summary Tag: Manual revert
(One intermediate revision by the same user not shown)
(No difference)

Latest revision as of 13:30, 18 March 2025

References[edit]